Literature DB >> 16647475

Plasma disappearance rate of indocyanine green in liver dysfunction.

P Faybik1, H Hetz.   

Abstract

The presence of hepatic dysfunction significantly affects the length of hospital stay and the outcome in critically ill patients. Considering the important partial hepatic functions of metabolism, synthesis, detoxification, and excretion, the worse clinical course of patients suffering from hepatic dysfunction is not surprising. The most often used indicator of hepatic dysfunction is bilirubin. However, bilirubin and other commonly used static laboratory tests provide only indirect measures of hepatic function. In contrast to these static tests, dynamic liver tests, such as indocyanine green (ICG) disappearance rate should provide better direct measures of the actual functional state of the liver at the time of assessment. The ICG is a water-soluble inert compound that is injected intravenously. It mainly binds to albumin in the plasma. ICG is then selectively taken up by hepatocytes, independent of adenosine triphosphate (ATP), and later excreted unchanged into the bile via an ATP-dependent transport system. The ICG is not metabolized; it does not undergo enterohepatic recirculation. Thus, ICG excretion rate in bile reflects the hepatic excretory function and hepatic energy status. Because of these features, ICG has been found to be useful to assess liver function in liver donors and transplant recipients, in patients with chronic liver failure, and as a prognostic factor in critically ill patients. Further trials concerning liver dysfunction have applied the noninvasive bedside assessment of ICG among other clinical variables to monitor the progress and/or the reversal of liver dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647475     DOI: 10.1016/j.transproceed.2006.01.049

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  25 in total

1.  [Indocyanine green plasma disappearance rate. Marker of partial hepato-splanchnic ischemia].

Authors:  O Thümer; E Hüttemann; S G Sakka
Journal:  Anaesthesist       Date:  2007-04       Impact factor: 1.041

2.  Laparoscopic Radiofrequency Ablation Should Be Considered a Safe Treatment for Hepatocellular Carcinoma Patients with Severe Cirrhosis and Impaired ICG-15 Test.

Authors:  Hongyu Li; Bo Li
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

3.  Potential factors dedicated to postoperative liver dysfunction in patients with normal preoperative ICG-15 clearance rate.

Authors:  Hongyu Li; Bo Li; Yonggang Wei
Journal:  Dig Dis Sci       Date:  2012-10-20       Impact factor: 3.199

Review 4.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation.

Authors:  S Lütje; M Rijpkema; W Helfrich; W J G Oyen; O C Boerman
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

6.  An accurate predictor of liver failure and death after hepatectomy: a single institution's experience with 478 consecutive cases.

Authors:  Zheng-Gui Du; Yong-Gang Wei; Ke-Fei Chen; Bo Li
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 7.  [Cholestasis and liver dysfunction in critical care patients].

Authors:  M Kredel; J Brederlau; N Roewer; C Wunder
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

8.  Hepatocyte-like cells derived from human amniotic epithelial cells can be encapsulated without loss of viability or function in vitro.

Authors:  Vijesh Vaghjiani; Vijayaganapathy Vaithilingam; Indah Saraswati; Adnan Sali; Padma Murthi; Bill Kalionis; Bernard E Tuch; Ursula Manuelpillai
Journal:  Stem Cells Dev       Date:  2014-01-21       Impact factor: 3.272

Review 9.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

10.  Role of the ¹³C-methacetin breath test in the assessment of acute liver injury in a rat model.

Authors:  Dong Zhu; Hui Zhang; Jing-Yi Mao; Hong-Yan Wang; Xin Li; You-Qing Xu
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.